AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 33 min read$SNDX

What Syndax Pharmaceuticals (SNDX) Said on Its Q3 Earnings Call

Syndax Pharmaceuticals (SNDX) reported Q3 earnings, highlighting Revuforj's increasing use before and after stem cell transplants. Niktimvo revenue rose 47% YoY to $67M, with collaboration revenue at $22.6M. The company expects more KMT2A patients to resume treatment post-transplant and anticipates meaningful revenue impact in 2027. Syndax plans to present Revuforj data in Q4 and advance its pipeline, including submissions for SNDX-4321 by late 2026.

Original reporting
finance.yahoo.com
Published Nov 3, 2026, 2:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 2:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
What Syndax Pharmaceuticals (SNDX) Said on Its Q3 Earnings Call — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$SNDXNeutralMed
01

Why it matters

The earnings beat and cash strength support a neutral‑to‑slightly‑positive outlook, while executive turnover adds a modest risk factor.

02

Market read

Earnings release provides fresh data for traders; modest upside potential but limited broader market impact.

03

What to watch

Potential future headwinds from upcoming trial timelines and reimbursement uncertainties for Revuforj.

Relevance 7/10Novelty 7/10Timing: after-hours Q3 earnings release

Background

Syndax Pharmaceuticals reported its Q3 2026 earnings, highlighting revenue growth from its two marketed products, Revuforj and Niktimvo, and provided updates on its AML pipeline and upcoming IND filings.

Company-level read

Ticker impact

$SNDXNeutralHigh confidence
Context

Q3 earnings disclosed $67M Niktimvo revenue (+47% YoY), cash $551M, CFO retirement and new CFO appointment, and updated clinical trial timelines.

Expected impact

likely modest upside as market prices in revenue growth, with neutral pressure from executive change

Evidence & confidence

Revenue growth and strong cash balance are positive fundamentals, while CFO turnover is a typical short‑term catalyst but not material enough to drive large moves.

Market effects

Sector

Positive signal for biotech sector as a small‑cap shows strong revenue growth and pipeline progress.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

Despite revenue growth, the lack of new guidance and CFO turnover could signal underlying execution risks.

Key entities

  • company
    Syndax Pharmaceuticals

    Biopharma focused on menin inhibitor Revuforj and GVHD drug Niktimvo.

  • executive
    Keith Goldan

    Outgoing CFO retiring after four years.

  • executive
    Aaron Ondrey

    Incoming CFO effective Nov. 9.

Read at source← All news

StorySyndax Pharmaceuticals reports Q3 2026 earnings with 82% revenue jump and narrowed loss

Also covered by

3 outlets

Related articles

NOV 3
$SNDXMed

Mizuho reiterates Outperform on Syndax stock, $43 target

Mizuho reiterated an Outperform rating and $43 target on Syndax Pharmaceuticals (SNDX) after its Q3 2026 earnings. Revenue was $60.7M for Revuforj, slightly below estimates but up 11% QoQ. The stock is near its 52-week low, down 38% YTD. Analysts maintain a Strong Buy consensus. Syndax reported total revenue of $83.3M, beating estimates, with an adjusted loss per share of $0.55.

investing.com2 min
NOV 2
$SNDXHighAI 8/10

Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update

Syndax Pharmaceuticals Inc (SNDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update • Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase – Revuforj ® (revumenib) net revenue of $60.7 million in 3Q26, a 90% y/y increase, underscores leadership in R/R

SEC EDGAR 8-K2 min
NOV 2
$SNDXLow

Syndax's new finance chief starts Nov. 9; his predecessor stays through year-end

Syndax Pharmaceuticals (SNDX) appointed Aaron A. Ondrey as CFO, effective Nov. 9, 2026. Keith A. Goldan, the outgoing CFO, will stay until year-end to support the transition. Ondrey has 25 years of biotech finance experience, previously serving as CFO at Beren Therapeutics and Rocket Pharmaceuticals. Goldan led Syndax's financial strategy during key growth periods, including FDA approvals for Revuforj and Niktimvo.

stocktitan.net1 min
NOV 2
$SNDXMed

About 20% more patients started Syndax's leukemia drug in Q3 than Q2; new data are expected in Q4.

Syndax Pharmaceuticals reported Q3 2026 revenue of $60.7M for Revuforj and $67.4M for Niktimvo, with Revuforj showing 90% YoY growth. The company expects new data on Revuforj in Q4 2026 from multiple clinical trials and real-world studies. Syndax plans to initiate the RAVEN trial in Q4 2026 and the MenTain trial in Q1 2027. The company will host a conference call today at 4:30 p.m. ET.

stocktitan.net2 min
OCT 14
$SNDXMedAI 8/10

Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal

Syndax Pharmaceuticals' stock fell 15.7% after its Phase II study of axatilimab in idiopathic pulmonary fibrosis (IPF) failed to meet the primary endpoint. The company will discontinue IPF development, but continues cGVHD programs. Axatilimab is already FDA-approved for cGVHD. Year-to-date, SNDX shares have dropped 33.6%.

zacks.com2 min